Drugmakers Try to Outflank White House in Trade Agreement

President Obama would like to cut the time that brand drugmakers have to test data on biologic medicines. PhRMA is arguing for the 12-year exclusivity period set forth in the Trans-Pacific Partnership, while GPhA argues for the president’s point of view.
The Hill